POXEL news, videos and press releases - Page 6
For more news please use our advanced search feature.
POXEL - More news...
POXEL - More news...
- Poxel to Report Full Year 2019 Financial Results and Host Conference Call on March 26, 2020
- Poxel Reports Financial Update for Cash and Revenue for the Full Year 2019 and Provides Corporate Update
- Poxel Presents New Preclinical Proof-of-Concept Results for PXL770 at the 3rd Annual Global NASH Congress
- Poxel Appoints Industry Leader Dr. David E. Moller as Chief Scientific Officer
- Poxel Announces its Financial Calendar for 2020
- Poxel and Sumitomo Dainippon Pharma Announce Positive Topline Phase 3 Results from TIMES 2 Trial of Imeglimin for the Treatment of Type 2 Diabetes in Japan and Successful Completion of the Pivotal TIMES Clinical Development Program
- Poxel Announces Participation at ODDO BHF Forum
- Poxel Announces Positive Results for PXL065 Phase 1b Trial and Provides Program Update
- Poxel Announces Participation at the H.C. Wainwright 3rd Annual NASH Investor Conference
- Poxel Reports Financial Results for the Third Quarter and Nine Months 2019 and Provides Corporate Update
- Poxel Announces Detailed Imeglimin Phase 3 TIMES 1 Results Presented at 55th Annual Meeting of the European Association for the Study of Diabetes
- Poxel Initiates Phase 1b Multiple Ascending Dose (MAD) Trial for NASH Drug Candidate, PXL065
- Poxel Announces Symposium Presentation for Imeglimin at 55th Annual Meeting of the European Association for the Study of Diabetes
- Poxel Announces Participation at the H.C. Wainwright 21st Annual Global Investment Conference
- Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial
- Poxel Announces Fourth Quarter and Full Year 2018 Financial Update
-
Poxel
-
Poxel
